MedTech Terms
    The authoritative reference
    All terms
    Clinical & TrialsClinical Evidence

    Adaptive Trial Design

    Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Adaptive designs include group sequential, sample-size re-estimation, response-adaptive randomization, and adaptive enrichment. Modifications must be pre-specified to preserve Type I error and trial integrity.
    What the regulation says
    The FDA provides guidance on adaptive designs for clinical trials, emphasizing their potential benefits while also highlighting the need for careful planning and pre-specification of adaptation rules to maintain statistical validity and control Type I error. The EU MDR (Medical Device Regulation) and IVDR (In Vitro Diagnostic Regulation) also implicitly support well-justified adaptive trial designs through their requirements for clinical evidence, provided that such designs are robust and scientifically sound.

    What this means in practice

    FDA actively encourages well-designed adaptive trials, especially in rare-disease and breakthrough device contexts.

    Examples

    • A sponsor conducting a pivotal trial for a novel cardiac stent pre-specifies criteria to re-estimate sample size at an interim analysis if the observed effect size is larger than initially assumed, thereby potentially reducing the overall trial duration.
    • A pharmaceutical company designing a Phase II oncology trial includes an adaptive enrichment strategy to focus enrollment on patient subgroups who show a better response to the investigational drug based on early interim data.
    • In a rare disease study, a manufacturer employs a response-adaptive randomization scheme, gradually assigning more patients to the treatment arm that demonstrates superior efficacy during the trial to maximize patient benefit.
    Common pitfalls
    • •Failing to pre-specify adaptation rules can compromise the integrity of the trial and lead to difficulties in regulatory acceptance.
    • •Inadequate justification for adaptations or poor statistical planning can result in biased outcomes or inflated Type I error rates.
    • •Overly complex adaptive designs can be difficult to implement and may introduce operational challenges.
    • •Failure to engage with regulatory bodies early in the planning of an adaptive trial may lead to delays or rejection of study results.
    • •Ignoring the potential impact of adaptations on blinding or randomization can undermine the validity of the trial.

    Frequently asked questions

    The primary benefit is greater flexibility to modify trial aspects, such as sample size or treatment arms, based on accumulating data, potentially leading to more efficient and ethical studies.

    Related terms

    Shared paths + category
    Clinical & Trials
    Pivotal Trial

    Definitive clinical study designed to establish safety and effectiveness for marketing authorization.

    Clinical Trials & Evidence · adjacent
    Clinical & Trials
    Bayesian Trial Design

    Trial design that uses Bayesian statistics, often incorporating prior data from related studies or registries.

    Same category
    Clinical & Trials
    Risk-Based Monitoring(RBM)

    Monitoring strategy that targets oversight resources to the highest-risk sites, processes, and data based on a documented risk assessment, replacing 100% source data verification.

    Clinical Trials & Evidence · adjacent
    Clinical & Trials
    Adverse Event(AE)

    Any untoward medical occurrence in a subject, whether or not related to the device.

    Clinical Trials & Evidence
    Clinical & Trials
    Clinical Evaluation Report(CER)

    Documented assessment of clinical data demonstrating EU MDR conformity for a device.

    Clinical Trials & Evidence
    Clinical & Trials
    Feasibility Study

    Small clinical study evaluating initial safety, usability, and design parameters of an investigational device.

    Clinical Trials & Evidence

    Latest in MedTech

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    FDA·1NIH·1ICH·1
    1. 1
      FDA - Clinical Trials and Human Subject Protection
      Verified
      FDAfda.gov
    2. 2
      ClinicalTrials.gov
      Verified
      NIHclinicaltrials.gov
    3. 3
      ICH Guidelines
      Verified
      ICHich.org

    Inline markers like [1] jump to the matching reference above.